Marco Kaiser

Dr. Marco Kaiser

GenExpress GmbH

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Emerging Infectious Diseases
Verified
Journal Article
Open access
CACornelia Adlhoch
Cornelia Adlhoch
MKMarco Kaiser
Marco Kaiser
ALAnna Loewa
Anna Loewa
MUMarkus Ulrich
Markus Ulrich
CFChristian Forbrig
Christian Forbrig
FLFabian H. Leendertz
Fabian H. Leendertz
During 2010–2011, we investigated interspecies transmission of partetraviruses between predators (humans and chimpanzees) and their prey (colobus monkeys) in Côte d’Ivoire. Despite widespread infection in all species investigated, no interspecies transmission could be detected by PCR and genome analysis. All sequences identified formed species- or subspecies (chimpanzee)-specific clusters, which supports a co-evolution hypothesis.

16 February 2017 in Microbiology Resource Announcements
Verified
Journal Article
Open access
PDF file
MKMarco Kaiser
Marco Kaiser
SKSaleem Kamili
Saleem Kamili
THTonya Hayden
Tonya Hayden
JBJohannes Blümel
Johannes Blümel
SBSally A. Baylis
Sally A. Baylis
We report here the sequence of a genotype 2a reference strain of hepatitis E virus (HEV), developed on behalf of the World Health Organization. The HEV reference strain is intended for use in assays based on nucleic acid amplification for the validation of HEV RNA detection.

19 April 2018 in Microbiology Resource Announcements
Verified
Journal Article
Open access
PDF file
MKMarco Kaiser
Marco Kaiser
DDDéborah Delaune
Déborah Delaune
OCOlivier Chazouillères
Olivier Chazouillères
JBJohannes Blümel
Johannes Blümel
ARAnne-Marie Roque-Afonso
Anne-Marie Roque-Afonso
SBSally A. Baylis
Sally A. Baylis
We report here the genome sequence of a hepatitis E virus (HEV) strain from a chronically infected immunodeficient patient. Full-length sequence analysis revealed a distinct HEV strain, of a tentative new subgenotype, clustering with viruses from rabbits. It is a World Health Organization reference strain for validation of nucleic acid testing.

19 November 2021 in Viruses
Verified
Journal Article
Open access
PDF file
AGAsish Kumar Ghosh
Asish Kumar Ghosh
MKMarco Kaiser
Marco Kaiser
MMMd. Maruf ahmed Molla
Md. Maruf ahmed Molla
TNTasnim Nafisa
Tasnim Nafisa
MYMahmuda Yeasmin
Mahmuda Yeasmin
SLSimon Lytton
Simon Lytton
Novel SARS-CoV-2 variants are emerging at an alarming rate. The delta variant and other variants of concern (VoC) carry spike (S)-protein mutations, which have the potential to evade protective immunity, to trigger break-through infections after COVID-19 vaccination, and to propagate future waves of COVID-19 pandemic. To identify SARS CoV-2 variants in Bangladesh, patients who are RT-PCR-positive for COVID-19 infections in Dhaka were screened by a RT-PCR melting curve analysis for spike protein mutations. To assess the anti-SARS CoV-2 antibody responses, the levels of the anti-S -proteins IgA and IgG and the anti-N-protein IgG were measured by ELISA. Of a total of 36 RT-PCR positive samples (75%), 27 were identified as delta variants, with one carrying an additional Q677H mutation and two with single nucleotide substitutions at position 23029 (compared to Wuhan-Hu-1 reference NC 045512) in the genome sequence. Three (8.3%) were identified as beta variants, two (5.5%) were identified as alpha variants, three (8.3%) were identified as having a B.1.1.318 lineage, and one sample was identified as an eta variant (B.1.525) carrying an additional V687L mutation. The trend of higher viral load (lower Cp values) among delta variants than in the alpha and beta variants was of borderline statistical significance (p = 0.045). Prospective studies with larger Bangladeshi cohorts are warranted to confirm the emergence of S-protein mutations and their association with antibody response in natural infection and potential breakthrough in vaccinated subjects.

18 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
AGAsish Kumar Ghosh
Asish Kumar Ghosh
OLOlfert Landt
Olfert Landt
MYMahmuda Yeasmin
Mahmuda Yeasmin
MSMohiuddin Sharif
Mohiuddin Sharif
RRRifat Hossain Ratul
Rifat Hossain Ratul
SLSimon Lytton
Simon Lytton
The clinical presentation of COVID-19 and the specific antibody responses associated with SARS-CoV-2 variants have not been investigated during the emergence of Omicron variants in Bangladesh. The Delta and Omicron variants were identified by post-PCR melting curve analysis of the spike (S) protein receptor binding domain amplicons. Anti-S-protein immunoglobulin-G anti-nucleocapsid (N)-protein immunoglobulin-G and immunoglobulin-A levels were measured by ELISA. The Delta variant was found in 40 out of 40 (100%) SARS-CoV-2 RT-PCR positive COVID-19 patients between 13 September and 23 October 2021 and Omicron variants in 90 out of 90 (100%) RT-PCR positive COVID-19 patients between 9 January and 10 February 2022. The Delta variant associated with hospitalization (74%, 80%, and 40%) and oxygen support (60%, 57%, and 40%) in the no vaccine, dose-1, and dose-2 vaccinated cases, respectively, whereas the Omicron COVID-19 required neither hospitalization nor oxygen support (0%, p < 0.0001). Fever, cough, and breathlessness were found at a significantly higher frequency among the Delta than Omicron variants (p < 0.001). The viral RNA levels of the Delta variant were higher than that of the Omicron variants (Ct median 19.9 versus 23.85; p < 0.02). Anti-spike protein immunoglobulin-G and anti-N-protein immunoglobulin-G within 1 week post onset of Delta variant COVID-19 symptoms indicate prior SARS-CoV-2 infection. The Delta variant and Omicron BA.1 and BA.2 breakthrough infections in the Dhaka region, at 240 days post onset of COVID-19 symptoms, negatively correlated with the time interval between the second vaccine dose and serum sampling. The findings of lower anti-spike protein immunoglobulin-G reactivity after booster vaccination than after the second vaccine dose suggest that the booster vaccine is not necessarily beneficial in young Bangladeshi adults having a history of repeated SARS-CoV-2 infections.